A Compassionate Use (CU) Program of Odronextamab
NCT05619367 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2025-12-23
Summary
Provide compassionate use of odronextamab
Conditions
- Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- B-Cell Non-Hodgkin Lymphoma (NHL)
- High-Grade B-Cell Lymphoma (HGBCL)
Interventions
- DRUG
-
Odronextamab
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
More Related Trials
-
Orelabrutinib, Rituximab and Combination Chemotherapy in Newly-diagnosed Aggressive B-cell Non-Hodgkin Lymphoma
NCT05097443 ·Status: UNKNOWN ·Phase: PHASE3
-
Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies
NCT02290951 ·Status: COMPLETED ·Phase: PHASE1
-
A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma
NCT06091254 ·Status: RECRUITING ·Phase: PHASE3
-
A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma
NCT06097364 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
R-CMOP in Patients With Primary Diffuse Large B-cell Lymphoma
NCT05777369 ·Status: UNKNOWN ·Phase: NA
-
Real-World Clinical Outcomes in Adult Patients Who Initiate Systemic Treatment for Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NCT05338892 ·Status: COMPLETED
-
Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
NCT03985696 ·Status: UNKNOWN ·Phase: NA
-
Study of SGR-1505 in Mature B-Cell Neoplasms
NCT05544019 ·Status: RECRUITING ·Phase: PHASE1
-
Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's Transformation
NCT06735664 ·Status: RECRUITING ·Phase: PHASE1
-
Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma
NCT00720135 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma
NCT01569750 ·Status: COMPLETED ·Phase: PHASE1
-
Oblimersen, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
NCT00070083 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
NCT00577629 ·Status: COMPLETED ·Phase: PHASE2
-
Ofatumumab for Initial Systemic Treatment of Indolent B-cell Lymphoma
NCT01239394 ·Status: COMPLETED ·Phase: PHASE2
-
A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma
NCT06149286 ·Status: RECRUITING ·Phase: PHASE3
-
Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma
NCT05459571 ·Status: COMPLETED ·Phase: PHASE2
-
HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL
NCT05176691 ·Status: WITHDRAWN ·Phase: PHASE1
-
FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma
NCT05934097 ·Status: WITHDRAWN ·Phase: PHASE1
-
Mitoxantrone Hydrochloride Liposome Combined With Rituximab and Lenalidomide (M+R2) in Patients With Relapsed and Refractory Diffuse Large B-Cell Lymphoma
NCT05575973 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
NCT04637763 ·Status: RECRUITING ·Phase: PHASE1
-
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
NCT00101010 ·Status: COMPLETED ·Phase: PHASE2
-
Orelabrutinib Combined With R-CDOP for DLBCL Patients With High-risk of CNS Relapse Defined by CNS-IPI
NCT06290817 ·Status: RECRUITING ·Phase: PHASE2
-
Pro-miniCHOP-like Regimen for Treatment-naive Elderly Patients
NCT05809180 ·Status: RECRUITING ·Phase: NA
-
A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
NCT02529852 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
NCT03332017 ·Status: COMPLETED ·Phase: PHASE2